Selected article for: "CoV protein and envelope protein"

Author: Rani, Jyoti; Bhargav, Anasuya; Khan, Faez Iqbal; Ramachandran, Srinivasan; Lai, Dakun; Bajpai, Urmi
Title: In silico prediction of natural compounds as potential multi-target inhibitors of structural proteins of SARS-CoV-2
  • Cord-id: 00cbc8gl
  • Document date: 2021_9_6
  • ID: 00cbc8gl
    Snippet: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a colossal loss to human health and lives and has deeply impacted socio-economic growth. Remarkable efforts have been made by the scientific community in containing the virus by successful development of vaccines and diagnostic kits. Initiatives towards drug repurposing and discovery have also been undertaken. In this study, we compiled the known natural anti-viral compounds using text mining of the literature and examin
    Document: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a colossal loss to human health and lives and has deeply impacted socio-economic growth. Remarkable efforts have been made by the scientific community in containing the virus by successful development of vaccines and diagnostic kits. Initiatives towards drug repurposing and discovery have also been undertaken. In this study, we compiled the known natural anti-viral compounds using text mining of the literature and examined them against four major structural proteins of SARS-CoV-2, namely, spike (S) protein, nucleocapsid (N) protein, membrane (M) protein and envelope (E) protein. Following computational approaches, we identified fangchinoline and versicolactone C as the compounds to exhibit strong binding to the target proteins and causing structural deformation of three structural proteins (N, S and M). We recommend the inhibitory effects of these compounds from our study should be experimentally validated against SARS-CoV-2. Communicated by Ramaswamy H. Sarma

    Search related documents:
    Co phrase search for related documents
    • accessible surface area and lopinavir ritonavir favipiravir: 1
    • accessible surface area and lopinavir ritonavir favipiravir remdesivir: 1
    • lopinavir ritonavir and low binding: 1, 2, 3